TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

Slides:



Advertisements
Similar presentations
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Advertisements

Steroids In caRdiac Surgery (SIRS) Trial
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
TOTAL Culprit lesion thrombus burden after manual aspiration thrombectomy or PCI alone in STEMI The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI.
on behalf of the TOTAL Investigators
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
ACS is a major public health challenge In the US:  Over 1.5 million people experience ACS annually 1 In the EU:  ACS is the most common cause of death,
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Randomized, double-blind, multicenter, controlled trial.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
on behalf of the TOTAL Investigators
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Why Radial Access Should be the Default for Women undergoing PCI?
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Is There a Role for Aspiration in STEMI?
Dabigatran in myocardial injury after noncardiac surgery
Median total new lesion volume
Modified Rankin score 0-2
A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Mancini JG, et al. Am J Cardiol.
What oral antiplatelet therapy would you choose?
A randomized comparison of RadIal Vs
Maintenance of Long-Term Clinical Benefit with
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Presentation transcript:

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators

TOTAL Disclosures TOTAL trial was funded by: Canadian Institutes of Health Research Canadian Network and Centre for Trials Internationally (CANNeCTIN) Medtronic Inc.

TOTAL The TOTAL Trial Study Design PCI Alone (only bailout thrombectomy) Routine Upfront Manual Thrombectomy followed by PCI Primary Outcome: CV death, MI, cardiogenic shock and class IV heart failure ≤180 days Safety Outcome: Stroke ≤30 days 1:1 Randomization between strategies Bailout Thrombectomy allowed if PCI alone strategy fails: Persistent TIMI 0 or 1 flow with large thrombus after balloon pre-dilatation Persistent large thrombus after stent deployment at target lesion STEMI with Primary PCI ≤12 hours of symptom onset Sample size of 10,700 for 80% power to detect a 20% Relative Risk Reduction Jolly SS, et al. Am Heart J (3):

TOTAL Key Findings of TOTAL Jolly SS, et al. N Engl J Med : No Difference in Primary Efficacy Outcome Increase in Stroke Hazard ratio 0.99 (95% CI ), P=0.86 Hazard ratio 2.00 (95% CI ), P=0.003

TOTAL Objectives of Detailed Stroke Analysis To better understand Stroke findings in TOTAL trial To explore: Timing of Stroke Stroke severity Subtypes of Stroke Independent Predictors of Stroke To incorporate findings into updated Meta-analysis

TOTAL Objectives of Detailed Stroke Analysis To understand stroke findings, specifically: Timing of Stroke Stroke severity Subtypes of Stroke Independent Predictors of Stroke To incorporate findings into updated Meta-analysis All strokes were adjudicated by Neurologists blinded to treatment

TOTAL PCI Procedure and Therapies over follow up Thrombectomy N=5033 PCI alone N=5030 P Upfront Glycoprotein IIb/IIIa22.7%25.4%P=0.002 PCI Procedure time (median) 39 min35 min<0.001 ≤ 5 French Catheters0.8%2.5%< French Catheters96.7%95.4%0.001 ≥ 2 guide catheters12.9%11.9%0.10 No differences in oral antiplatelet, anticoagulant or anti-hypertensive therapy over follow up

TOTAL Landmark Analysis for Stroke Thrombectomy (N=5033) (%) PCI alone (N=5030) (%) HR95% CI 0 to 48 hours15 (0.30%)5 (0.10%) >48 hours to <7 days 5 (0.10%)4 (0.08%) to <30 days13 (0.26%)7 (0.14%) − to <90 days11 (0.23%)8 (0.16%) to 180 days8 (0.17%)2 (0.04%)

TOTAL Stroke Severity Rankin Score Thrombectomy (N=5033) (%) PCI alone (N=5030) (%) HR95% CIp Minor or no disability (0-2) 18 (0.4%)13 (0.3%) Major disability or fatal (3-6) 35 (0.7%)13 (0.3%) Full recovery from all symptoms4Patient needs help from another person to perform everyday activities 2Persistent symptoms which do not limit patient’s functional status 5Patient incapacitated, unable to perform everyday activities even with help 3Some functional impairment but patient can manage all activities independently 6Death Rankin Score

TOTAL Stroke Subtype during 180 days Thrombectomy (N=5033) (%) PCI alone (N=5030) (%) HR95% CIp Ischemic37 (0.7%)21 (0.4%) Primary hemorrhagic10 (0.2%)2 (0.04%) Uncertain Etiology5 (0.1%)3 (0.1%)

TOTAL Cumulative Ischemic Neurologic Events (includes TIA) over time Thrombectomy (N=5033) (%) PCI alone (N=5030) (%) HR95% CIp 12 hours6 (0.12%)4 (0.08%) hours11 (0.22%)5 (0.10%) hours15 (0.30%)6 (0.12%) hours19 (0.38%)11 (0.22%) days21 (0.42%)14 (0.28%) days28 (0.56%)16 (0.32%) days35 (0.70%)19 (0.38%) days46 (0.91%)28 (0.56%) days52 (1.03%)29 (0.58%)

TOTAL Subgroup Analysis Stroke OVERALL TIMI Thrombus Grade: ≥4≥4 <4 Initial TIMI Flow: Site Primary PCI Volume: Tertile 1 Tertile 2 Tertile 3 History of Hypertension: No Yes Age: <=65 yrs >65 yrs Previous Stroke: No Yes Gender: Male Female Access site: Radial Femoral Operator thrombectomy Volume: Tertile 1 Tertile 2 Tertile Thrombectomy (%) PCI Alone (%) P (INTERACTION) Favours ThrombectomyFavours PCI Alone

TOTAL Independent Predictors of Stroke Thrombectomy vs PCI Age per 10 years Female Peripheral Vascular Disease Previous stroke Prior diabetes Intra aortic balloon CABG TIMI thrombus grade HR (95%CI) 2.00 ( ) 1.27 ( ) 2.10 ( ) 2.56 ( ) 2.54 ( ) 2.41 ( ) 2.98 ( ) 2.16 ( ) 1.20 ( ) Stepwise Cox Regression Model

TOTAL Meta-Analysis for Stroke 0.8% Thrombectomy vs. 0.5% PCI alone, OR 1.59; 95% CI , p=0.01

TOTAL Meta-Analysis for Mortality 3.8% Thrombectomy vs. 4.3% PCI alone, OR 0.87; 95% CI , p=0.05

TOTAL Mortality of Stroke within 180 days 30.8% 3.4% Months of Follow-up Cumulative % of Death With Stroke Without Stroke Hazard ratio, (95%CI, ); P<0.0001) No. at Risk With Stroke Without Stroke

TOTAL Conclusions Routine thrombectomy was associated with increased risk of stroke that was evident within 48 hours Increase in primarily ischemic strokes but also hemorrhagic strokes Future trials of thrombectomy devices need to carefully collect stroke outcomes (safety) to determine safety and in addition to efficacy